Fig. 6: Aberrant Wnt/β-catenin signaling in human T-lymphoblastic lymphoma, and TG level associated survival and Ex in PTCL patients.
From: Aberrant lipid metabolism renders an aggressive behavior of T-lymphoblastic lymphoma in a MASH model
A, B Western blot analysis of AXIN-1 and phosphorylated β-catenin at thr41/ser45 from the OP-challenged HH cells treated with 1 μM XAV939 treatment for 16 h. C, D Western blot analysis of phosphorylated GSK-3β at ser9 and phosphorylated β-catenin at thr41/ser45 from the OP-challenged HH cells treated with 20 mM LiCl for 16 h. E Trans-well assay to determine the migratory ability of HH cells which were challenged with OP and treated with 20 mM LiCl and 1 μM XAV939 for 16 h. OP: a mixture of oleic acid and palmitic acid (2:1); p-β-Cat: phosphorylated β-catenin; p-GSK-3β: phosphorylated GSK-3β; Ex: extranodal lymphoma. F Serum TG levels in the PTCL patients with/without Ex. G Kaplan–Meier plot of overall survival in the PTCL patients diagnozed hypertriglyceridemia (TG level ≥1.8 mmol/L) compared to the patients with normal serum TG levels. Black dash: 24 months. H Kaplan–Meier plot of time to next anti-lymphoma treatment (TTNT) in PTCL patients with/without extranodal lymphoma and with/without hypertriglyceridemia. Orange dash in (H): median TTNT.
